Jaguar Health Signs Agreement for Non-dilutive Financing Transaction Involving the Sale of Royalty Rights Related to Future Mytesi (Crofelemer) Revenue Stream for $5 Million, with Possible Future Tranches in 2021, Totaling $16 MillionJaguar Health • October 1st, 2020 • Jaguar Health, Inc. • Pharmaceutical preparations
Contract Type FiledOctober 1st, 2020 Company IndustrySan Francisco, CA (October 1, 2020): Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company") today announced that the Company has signed an agreement with a secured lender (the “Lender”) for a non-dilutive royalty financing transaction, pursuant to which Jaguar would sell to the Lender for an aggregate purchase price of $5 million (the “Royalty Purchase Price”) a royalty interest entitling the Lender to receive 2.0x the Royalty Purchase Price of future royalties on sales of Mytesi® (crofelemer) and certain up-front license fees and milestone payments from licensees and/or distributors (the “Royalty Repayment Amount”). Upon mutual agreement, the parties may agree to consummate additional royalty financings of $5 million and $6 million in February 2021 and July 2021, respectively, for a total of $16.0 mm.